Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

In a recent study published in the Lancet, researchers evaluated the safety and efficacy of tixagevimab–cilgavimab, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) combination in patients with mild to moderate coronavirus disease 2019 (COVID-19).

Related Keywords

Japan ,United States ,America , ,World Health Organization ,Drug Administration ,Latin America ,Clinical Progression Scale ,Cox Regression ,Coronavirus Disease Covid 19 ,Efficacy ,Ntibody ,Clinical Trial ,Coronavirus ,Wood ,Monoclonal Antibody ,Placebo ,Espiratory ,Cars ,Ars Cov 2 ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Yndrome ,